These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 32956495)

  • 1. Dexamethasone, pro-resolving lipid mediators and resolution of inflammation in COVID-19.
    Andreakos E; Papadaki M; Serhan CN
    Allergy; 2021 Mar; 76(3):626-628. PubMed ID: 32956495
    [No Abstract]   [Full Text] [Related]  

  • 2. Activating endogenous resolution pathways by soluble epoxide hydrolase inhibitors for the management of COVID-19.
    Manickam M; Meenakshisundaram S; Pillaiyar T
    Arch Pharm (Weinheim); 2022 Mar; 355(3):e2100367. PubMed ID: 34802171
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pro resolving inflammatory effects of the lipid mediators of omega 3 fatty acids and its implication in SARS COVID-19.
    Regidor PA; Santos FG; Rizo JM; Egea FM
    Med Hypotheses; 2020 Dec; 145():110340. PubMed ID: 33069094
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Parenteral fish oil: An adjuvant pharmacotherapy for coronavirus disease 2019?
    Torrinhas RS; Calder PC; Lemos GO; Waitzberg DL
    Nutrition; 2021 Jan; 81():110900. PubMed ID: 32738510
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Induction of Exaggerated Cytokine Production in Human Peripheral Blood Mononuclear Cells by a Recombinant SARS-CoV-2 Spike Glycoprotein S1 and Its Inhibition by Dexamethasone.
    Olajide OA; Iwuanyanwu VU; Lepiarz-Raba I; Al-Hindawi AA
    Inflammation; 2021 Oct; 44(5):1865-1877. PubMed ID: 33860869
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of specialized pro-resolving lipid mediators and their receptors in virus infection: a promising therapeutic strategy for SARS-CoV-2 cytokine storm.
    Lee CH
    Arch Pharm Res; 2021 Jan; 44(1):84-98. PubMed ID: 33398691
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Resolvin D1 and D2 reduce SARS-CoV-2-induced inflammatory responses in cystic fibrosis macrophages.
    Recchiuti A; Patruno S; Mattoscio D; Isopi E; Pomilio A; Lamolinara A; Iezzi M; Pecce R; Romano M
    FASEB J; 2021 Apr; 35(4):e21441. PubMed ID: 33749902
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Specialized Pro-Resolving Mediators in Neuroinflammation: Overview of Studies and Perspectives of Clinical Applications.
    Valente M; Dentoni M; Bellizzi F; Kuris F; Gigli GL
    Molecules; 2022 Jul; 27(15):. PubMed ID: 35956787
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Resolution of acute inflammation in the lung.
    Levy BD; Serhan CN
    Annu Rev Physiol; 2014; 76():467-92. PubMed ID: 24313723
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pro-resolving lipid mediators are leads for resolution physiology.
    Serhan CN
    Nature; 2014 Jun; 510(7503):92-101. PubMed ID: 24899309
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Resolvins, Protectins, and Maresins: DHA-Derived Specialized Pro-Resolving Mediators, Biosynthetic Pathways, Synthetic Approaches, and Their Role in Inflammation.
    Ferreira I; Falcato F; Bandarra N; Rauter AP
    Molecules; 2022 Mar; 27(5):. PubMed ID: 35268778
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of dexamethasone on SARS-CoV-2 concentration kinetics and antibody response in hospitalized COVID-19 patients: results from a prospective observational study.
    Mühlemann B; Thibeault C; Hillus D; Helbig ET; Lippert LJ; Tober-Lau P; Schwarz T; Müller MA; ; Witzenrath M; Suttorp N; Sander LE; Drosten C; Jones TC; Corman VM; Kurth F
    Clin Microbiol Infect; 2021 Oct; 27(10):1520.e7-1520.e10. PubMed ID: 34139335
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Specialized proresolving mediators in infection and lung injury.
    Sandhaus S; Swick AG
    Biofactors; 2021 Jan; 47(1):6-18. PubMed ID: 33249673
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effects of perioperative dexamethasone on eicosanoids and mediators of inflammation resolution: A sub-study of the PADDAG trial.
    Barden A; Phillips M; Shinde S; Corcoran T; Mori TA
    Prostaglandins Leukot Essent Fatty Acids; 2021 Oct; 173():102334. PubMed ID: 34455200
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dexamethasone may improve severe COVID-19 via ameliorating endothelial injury and inflammation: A preliminary pilot study.
    Kim WY; Kweon OJ; Cha MJ; Baek MS; Choi SH
    PLoS One; 2021; 16(7):e0254167. PubMed ID: 34214123
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Obesity-Driven Deficiencies of Specialized Pro-resolving Mediators May Drive Adverse Outcomes During SARS-CoV-2 Infection.
    Pal A; Gowdy KM; Oestreich KJ; Beck M; Shaikh SR
    Front Immunol; 2020; 11():1997. PubMed ID: 32983141
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is dexamethasone an effective treatment for severe COVID-19 patients: Journal Club review.
    Chan K; Sharif S; Rochwerg B
    CJEM; 2021 Mar; 23(2):159-161. PubMed ID: 33534117
    [No Abstract]   [Full Text] [Related]  

  • 18. An Impaired Inflammatory and Innate Immune Response in COVID-19.
    Park SH
    Mol Cells; 2021 Jun; 44(6):384-391. PubMed ID: 34098591
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Beyond dexamethasone, emerging immuno-thrombotic therapies for COVID-19.
    Jensen MP; George M; Gilroy D; Sofat R
    Br J Clin Pharmacol; 2021 Mar; 87(3):845-857. PubMed ID: 32881064
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acute severe SARS COVID-19 patients produce pro-resolving lipids mediators and eicosanoids.
    Regidor PA; De La Rosa X; Santos FG; Rizo JM; Gracia Banzo R; Silva RS
    Eur Rev Med Pharmacol Sci; 2021 Nov; 25(21):6782-6796. PubMed ID: 34787883
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.